Immunotherapy Combinations for Esophageal Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that chronic therapy with certain anti-inflammatory or anti-platelet agents is not allowed, and treatment with anticoagulation agents like warfarin is excluded. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug combination for esophageal cancer?
Research shows that combining drugs like cisplatin and 5-fluorouracil (5-FU) can have a synergistic effect, meaning they work better together, in treating esophageal cancer. Additionally, immunotherapy drugs like nivolumab have been shown to improve survival rates in esophageal cancer patients when used with chemotherapy.12345
Is the combination of immunotherapy and chemotherapy safe for esophageal cancer?
Studies have shown that combinations of drugs like 5-fluorouracil, cisplatin, paclitaxel, and oxaliplatin, often used with radiotherapy, have been evaluated for safety in esophageal cancer. While these treatments can be effective, they may also cause side effects, which vary among patients. It's important to discuss potential risks with your healthcare provider.678910
How is the drug combination of 5-Fluorouracil, Atezolizumab, Cisplatin, Oxaliplatin, and Tiragolumab unique for esophageal cancer?
This drug combination is unique because it includes Atezolizumab and Tiragolumab, which are immunotherapy drugs that help the immune system fight cancer, alongside traditional chemotherapy drugs like 5-Fluorouracil, Cisplatin, and Oxaliplatin. This approach aims to enhance the body's natural defenses against cancer, potentially offering a new option for patients with esophageal cancer.1241112
What is the purpose of this trial?
This trial tests a combination of chemotherapy and immunotherapy in patients with advanced gastric and esophageal cancers. It aims to see if this combination is safe and effective, especially for those who haven't responded to other treatments or haven't been treated before. Combination therapies involving chemotherapy and immunotherapy have shown promising results in initial clinical trials for cancer treatment.
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
Adults with advanced gastric or gastroesophageal junction cancer, or esophageal cancer who have not had certain treatments. They must be in good physical condition (ECOG 0-1), expect to live at least 3 months, and agree to use contraception. Excluded are those with uncontrolled hypertension, recent severe infections, significant heart disease, autoimmune diseases, HIV/HBV/HCV infection, CNS metastases risk factors for bleeding disorders.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive immunotherapy-based treatment combinations, including atezolizumab with various agents, depending on the cohort and arm
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term if they progress on initial treatment
Treatment Details
Interventions
- 5-Fluorouracil (5-FU)
- Atezolizumab
- Cisplatin
- Leucovorin
- Linagliptin
- Oxaliplatin
- Paclitaxel
- Ramucirumab
- Tiragolumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University
BioLineRx, Ltd.
Industry Sponsor
Halozyme Therapeutics
Industry Sponsor